TaiwanJ Pharmaceuticals has signed a $26 million contract with Shanghai, China-based Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia. JKB-122 is a phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate. Newsoara will be responsible for the clinical development and market commercialization of JKB-122 in Asia, except Taiwan.   According to the agreement, TaiwanJ will receive $2 million upfront and up to $24 m...